Mithun-Saarkar

Portfolio, Equity Research and Investment🧵
I make detailed threads on biz to help investors understand the future of biz

[Mithun-Saarkar @TatitPanji]

Why power Transmission is a theme for next 5-6 years , what's the reason for this drive , huge growth , lets understand in simple way .
These 3 are driving factors.
1. Rising power consumption
2. Govt. Renewable push
3. Grid Moderisation

[Mithun-Saarkar @TatitPanji]

My portfolio currently consits of following sectors :
1. Auto anc and auto EV
2. Consumption ( retails)
3. Nbfcs
4. Microfinance stocks
5. Chemicals
6. Logistics
7. Ai dc proxys ( top wt )
8. Pharma ( 2nd top wt)
9. Aerospace and defence
10. Power transmission

These 10

[Mithun-Saarkar @TatitPanji]

Give an opportunity : When u are reading or studying a company and if u felt that it's interesting and looks promising, don't just keep in watch list, put some some money and add 1-2% in it and invest, u never know which stocks is that one stock u are searching.
Who know after 1

[Mithun-Saarkar @TatitPanji]

2/ Q1 was strong 👉growth quality was good

🔹Revenue: 1,964 cr | +27.6% YoY
🔹Organic growth: +27.3%
🔹Organic CC growth: +14.9%
🔹Adj EBITDA: 472 cr | +27.9%
🔹EBITDA margin: 24%
🔹Adj PAT: 270 cr | +35.1%

Mgmt said there was no pricing-led growth.

[Mithun-Saarkar @TatitPanji]

Sagility Q1 FY27 , Concall Updates : Strong execution, but Q2 is the key test

1/ Biz:

Sagility is a healthcare-focused BPM/operations company with 89.6% revenue from payers and 10.4% from providers.

Core areas include claims, clinical/care management, quality, payment

[Mithun-Saarkar @TatitPanji]

The Anti thesis to Divgi :
Key Concerns or Risks to monitor 💡

1. Q1 Margin Normalisation 👉 mgmt sats margins to nornalise 20-22 kind

2. Indonesia biz : Indonesia biz is good for FY27, but then how much or what % is recurring we need to see.

3. EV opportunity are delaying :

[Mithun-Saarkar @TatitPanji]

Divgi TorqTransfer Systems:

Q1 FY27 Concall : Entering the “next orbit”? Part -1

1/
Divgi TorqTransfer Systems just delivered its best-ever quarter.

But the bigger story is not just Q1 numbers.

It is the transition from a transfer-case/component supplier to a broader

[Mithun-Saarkar @TatitPanji]

Studying Divgi , will post tonight .
Stay informed.

Divgi call is interesting 💡

[Mithun-Saarkar @TatitPanji]

When I post well researched post ,I dont get replies and get very low engagement, and when in shit posts I get a lot of Engagement , probably thats what the algo is designed for.

Accha hai 😀😀😀

[Mithun-Saarkar @TatitPanji]

Concentrate bets never worked out fir me.
Whenever I concebtrated like from 20 to 10 or 5 , baring those 5 the rest 25 did well such great luck i have .
😀😀😀😀😀.

And another example , if i made 20 from 30 names, the left out 10 names did better than the chosen 20 🤣🤣🤣

[Mithun-Saarkar @TatitPanji]

Valuation drivers : The mkt gives a certain valuation or PE for reasons, in the thread below I tried to explain few pointers do read.

[Mithun-Saarkar @TatitPanji]

Manorama Industries : New Product Launches and developments :

Manorama is expanding beyond its core CBE/stearin portfolio into more application-specific specialty fats:

New Developments :
• Milcocream FF81 – caramel & nougat applications
• Milcocream 1082 – truffle filling

[Mithun-Saarkar @TatitPanji]

“We are very much positive that our new investments… should give us a good, steady, healthy growth for our near term vision for 3 to 5 years.”

“We are steadily advancing our aspiration of becoming the partner of choice for the world's leading food and confectionery and

[Mithun-Saarkar @TatitPanji]

Stallion India Fluorochemicals Q1 FY27 Concall Updates:

1/The Q1 numbers were strong.

But the bigger story is what is happening underneath:
Distribution → Backward integration → Manufacturing → Specialty & high-purity gases

Mgmt continues to guide for 30–35% revenue

[Mithun-Saarkar @TatitPanji]

Stallion Q1 Update on R32 capex at Bhilwara: Target to complete by December 2026 end.

[Mithun-Saarkar @TatitPanji]

I dont try to make quick money , I look for longterm structural plays( 2+3+ years atleast) i buy at ATH , after my buying many fall 15-20-25%, normal clearly shows i cant time it .

But thats nature of mkts, eventually if the longterm thesis is correct i make money, tracking in

[Mithun-Saarkar @TatitPanji]

Cupid : I valued the company at max 40000 cr mcap quite some time back and exactly at that mcap yestetday the profit booking came .

40000 cr mcap is a hurdle and needs fresh triggers .

Do study no recommendations .
Valuations are a forward looking game.

Booking profits is

[Mithun-Saarkar @TatitPanji]

Olectra GreenTech Q1 FY27 Concall Updates
The EV story is entering its next phase. 🧵

1/
Olectra is no longer just an electric-bus story.
The business is now entering 3 new phases:

→ Bus volume ramp-up
→ New-generation bus + truck platforms
→ Insulator business expansion

[Mithun-Saarkar @TatitPanji]

Olectra Greentech Q1 FY27 Concall Updates :

2/ Q1 FY27:

• Revenue: 575.5 Cr | +66% YoY
• EBITDA: 72.9 Cr | +30%
• PBT: 34.7 Cr | +3%

Mobility revenue grew 69% YoY, while vehicles sold increased from 161 → 358.

But profit growth lagged revenue growth due to margin

[Mithun-Saarkar @TatitPanji]

Look out for 👉
Players Whose Capex Is Nearing Completion:

The Operating Leverage Inflection In capital-intensive businesses, the real payoff often arrives not during the heavy investment phase but after major projects are commissioned and begin ramping. Fixed costs

[Mithun-Saarkar @TatitPanji]

The Chemical Space : Srudy list.
After studying nearly 25-30 cos , i have hand picked these top 10 names which i like from this space based on future outlook and growth road map.

No recommendations ,but just a smaller basket for further study .

1. Yasho Ind
2. Neogen Chemicals